Evaluation of anti-tumor effect of epothilone B on human lung cancer A549 cell in vitro and in vivo

Abstract

Abstract: AIM: To investigate the inhibitory effect of Epothilone B on the human lung cancer A549 cell line in vitro and in vivo. METHODS: The MTT method was used to evaluate the inhibitory effect of Epothilone B on proliferation of A549 cell line for 72 h; Xenotransplanted nude mice model with human lung cancer A549 was used to evaluate Epothilone B antitumor activity on 1.0, 0.5, 0.25 mg/kg concentration. RESULTS: MTT inspection showed that the IC₅₀ of Epothilone B was (0.53±0.11) nmol/L. In addition, the maximum inhibition rate was 68.6%. The data from experiments in vivo indicated that Epothilone B had a strong inhibitory effect in dose-dependent manner on A549 human lung cancer xenografts in nude mice. The inhibition rates were 78.6%, 58.8% and 48.3% for the first experiment when the administrated concentration was 1.0, 0.5, 0.25 mg/kg, and the inhibition rates of the second experiment were 84.2%, 76.0% and 68.2%, moreover, the inhibition rates of paclitaxel at a multiple dose of 15 mg/kg were 56.0% and 85.7%, respectively. CONCLUSION: Our results indicate that Epothilone B can inhibit the proliferation of A549 cell line in vitro and the growth of xenotransplanted human tumors in nude mice.

Key words: Epothilone B, A549, human lung cancer, anti-tumor effect, xenograft

CLC Number:

R965.2

YANG De-xuan, LI Lin-na, WANG Shan-shan, YUAN Shou-jun. Evaluation of anti-tumor effect of epothilone B on human lung cancer A549 cell in vitro and in vivo[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1201-1205.

References 15

[1]	许金华, 谭翔文, 秦勇, 等. 5-烯丙基-7-二氟亚甲基白杨素对人肺腺癌A549细胞裸鼠移植瘤生长的影响[J]. 中国实验动物学报, 2009, 17(5): 373-377.
[2]	陶黎阳, 黎渐英. 肺癌A549耐药裸鼠移植瘤模型的建立[J]. 中国医药指南, 2011, 9(7): 13-14.
[3]	顾亮, 赵恬, 钦光跃. 吉非替尼对比培美曲塞二线治疗晚期非小细胞肺癌的临床研究[J]. 中国临床药理学与治疗学, 2012, 17(5): 569-573.
[4]	Höfle G, Bedorf N, Steinmetz H, et al.Epothilone A and B-novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and conformation in solution[J]. Angew Chem Int Ed Engl, 1996, 35(13): 1567-1569.
[5]	Nicoletti MI, Valoti G, Giannakakou P, et al.Expression of β-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents[J]. Clin Cancer Res, 2001, 7(9): 2912-2922.
[6]	Nettles JH, Li H, Cornett B, et al.The binding mode of epothilone A on α, β-tubulin by electron crystallography[J]. Science, 2004, 305(5685): 866-869.
[7]	Kowalski RJ, Giannakakakou P, Hamel E.Activities of the microtubule-stabilizing agents epothilone A and B with purified Tubulin and in cells rasistant to Paclitaxel (Taxol○R)[J]. J Biol Chem, 1997, 272(4): 2534-2541.
[8]	Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action[J]. Cancer Res, 1995, 55(11): 2325-2333.
[9]	Nicolaou KC, Roschangar F, Vourloumis D.Chemical Biology of Epothilones[J]. Angew Chem Int Ed, 1998, 37(15): 2014-2045.
[10]	Lee FY, Borzilleri R, Fairchild CR, et al.BMS-247550: A novel epothilone analog with amode of action similar to paclitaxel but possessing superior antitumor efficacy[J]. Clin Cancer Res, 2001, 7(5): 1429-1437.
[11]	Nicolaou KC, Ritzen A, Namoto K.Recent developments in the chemistry, biology and medicine of the epothilones[J]. Chem Commun, 2001 7(17): 1523-1535.
[12]	Pivot X, Dufresne A, Villanueva C.Efficacy and safety of ixabepilone, a novel epothilone analogue[J]. Clin Breast Cancer, 2007, 7(7): 543-549.
[13]	Tommasi S, Mangia A, Lacalamita R, et al.Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of β-tubulins[J]. Int J Cancer, 2007, 120(10): 2078-2085.
[14]	Kamath AV, Chang M, Lee FY, et al.Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog[J]. Cancer Chemother Pharmacol, 2005, 56(2): 145-153.
[15]	Edelman MJ, Shvartsbeyn M.Epothilones in development for non-small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance[J]. Clin Lung Cancer, 2012, 13(3): 171-180.